tbuckley/cabot-search huggingface dataset:
Rituximab and Interleukin 2 (IL2) as treatment for CD20+ non-Hodgkin's lymphoma (NHL) following autologous peripheral blood stem cell transplant (ASCT)
Authors: L. A. Holmberg, D. G. Maloney, W. I. Bensinger
Journal: Journal of Clinical Oncology (2004)

6534 Background: Relapse is a problem after ASCT for NHL. The immune system is not active early post-ASCT. Adding immunotherapy may decrease relapse and prolong survival. In an initial phase I/II trial, we determined the MTD of IL2. This dose increased the number of immune cells and expression of lytic activity against NK and LAK targets. Rituximab is a monoclonal antibody directed against CD20 on B cells. Rituximab has anti-proliferative effect, induces apoptosis and lyses tumors using Complement and ADCC. Since Rituximab's effectiveness after ASCT may be limited by poor immune function, it seemed reasonable, based on our previous trial, to study the combination of Rituximab/IL2. Methods: From 1/2000, 18 patients (indolent n=1; aggressive n=17) after ASCT for CD20+ NHL were treated with Rituximab/IL2. Patients began therapy at platelet count (untransfused) > 30,000 cells/mm3, ANC >1,000 cells/mm3, TB ≤ 2 mg/dl, SGOT/SGPT ≤ 2.5 x ULN and creatinine ≤ 2 mg/dl. Patients could not be on steroid therapy, have active infection, or have evidence of disease progression, pericardial effusion, pleural effusion or ascites. The treatment was: IL2 at 0.6x106 iu/m2/day sc for 12 weeks, followed by 1.4x106 iu/m2 sc 3 times/week for an additional 12 weeks. Rituximab was given 375 mg/m2 iv (total of four doses): beginning 1 day prior to IL2, between days 25–30, 50–55 and 75–80 of IL-2 therapy. NCI Common Toxicity Criteria were used for grading toxicity. Results: The median time to start of therapy was 74 days post-transplant (range 49–100). Four patients met early toxicity stopping rules grade 3 (infection, n=2) and grade 4 (neutropenia, n=2). Neutropenia responded to G-CSF, within 3–8 days. The infections seen were: pneumonia (n=2), oral thrush (n=2), oral herpes (n=1), UTI (n=1) and URTI (n=2). The only reoccurrence was in a mantle cell patient who stopped therapy at 4 weeks and died on day +149 post transplant. Seventeen patients remain alive with no evidence of relapse, with a median follow-up of 22 months (8–42). Conclusions: Rituximab/IL2 is well tolerated after ASCT and may decrease relapses. A randomized study is warranted. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Genentech Genentech Genentech
Tumor Promotion in the Forestomach Epithelium of Mice by Oral Administration of Citrus Oils&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;&lt;xref ref-type="fn" rid="FN3"&gt;3&lt;/xref&gt;
Authors: Field, Winifred E. H., Roe, Francis J. C.
Journal: JNCI Journal of the National Cancer Institute (1965)

Journal Article Tumor Promotion in the Forestomach Epithelium of Mice by Oral Administration of Citrus Oils Get access Winifred E. H. Field, Winifred E. H. Field Cancer Research Department, London Hospital Medical College, London, England Search for other works by this author on: Oxford Academic PubMed Google Scholar Francis J. C. Roe Francis J. C. Roe Cancer Research Department, London Hospital Medical College, London, England Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 35, Issue 5, November 1965, Pages 771–787, https://doi.org/10.1093/jnci/35.5.771 Published: 01 November 1965 Article history Received: 10 November 1964 Published: 01 November 1965
Prognostic factors in childhood acute myelogenous leukemia.
Authors: H E Grier, R D Gelber, B M Camitta, M J Delorey, M P Link, K N Price, P R Leavitt, H J Weinstein
Journal: Journal of Clinical Oncology (1987)

The prognostic significance of initial clinical and laboratory parameters was evaluated in 125 children with acute myelogenous leukemia (AML) treated on two consecutive protocols (VAPA and 80-035). Both protocols used an anthracycline with cytosine arabinoside (ara-C) for induction therapy followed by 12 to 14 months of intensive sequential postremission chemotherapy. Results are similar for the two treatment regimens. Seventy-two percent of patients achieved a complete remission, with 42% projected 5-year disease-free survival for the complete responders. Monocytic or myelomonocytic leukemic subtype (French-American-British [FAB] types M4 and M5), WBC count less than 100,000/microL, and age less than 2 years at diagnosis all predicted increased risk of relapse and decreased overall survival in univariate analyses. FAB subtype and high white count continued to predict for an increased risk of relapse in multivariate analyses and only M5 leukemic subtype independently predicted for poor survival. Patients with M4 or M5 leukemic subtype had a higher incidence of initial relapses in the CNS. The addition of intrathecal cytosine arabinoside in the second protocol, 80-035, decreased the percentage of patients with initial failure in the CNS, but did not improve overall survival. Improved CNS prophylaxis, better systemic therapy, and/or different treatment strategies are needed to improve therapy in these high-risk patients.
Ephrin-A1 induces tumor cell migration via a Rho GTPase and Jak kinase-dependent pathway
Authors: Monica A. Parker, Dana M. Brantley-Sieders, Wei B. Fang, Jin Chen
Journal: Cancer Research (2005)

5471   It is increasingly clear that the Eph family of receptor tyrosine kinases play a critical role in tumor progression. In particular, one family member, the EphA2 receptor, is overexpressed in both tumor cells and tumor endothelium in a variety of cancers. In addition, the extent of EphA2 overexpression correlates with tumor malignancy. In this study using a cell culture model system and a soluble ligand molecule, we show that ephrin-A1 induces tumor cell migration by activating members of the Rho family of GTPases and Jak kinases. The Ephrin-A1 ligand also induces EphA2 internalization via a clathrin-mediated endocytic pathway. Blocking EphA2 receptor endocytosis either by potassium depletion or sucrose pre-treatment results in sustained EphA2 receptor phosphorylation and Jak kinase activation. These results suggest a role for EphA2 receptor endocytosis in down-regulation of EphA2 signaling. We are currently dissecting signaling events downstream of Rho and Jak that regulate tumor cell migration. We are also exploring alternative signaling pathways that may require EphA2 receptor internalization.
The neuroleptic malignant syndrome and acute renal failure.
Authors: B N Becker, N Ismail
Journal: Journal of the American Society of Nephrology (1994)

Rhabdomyolysis is a clinical disorder arising from skeletal muscle injury. Many potentially fatal complications may develop after rhabdomyolysis, including hyperkalemia, disseminated intravascular coagulation, and acute renal failure. Both traumatic and nontraumatic causes of rhabdomyolysis are seen. Frequently, nontraumatic rhabdomyolysis is associated with the use of common drugs. We report such a case--a patient afflicted with the neuroleptic malignant syndrome (NMS). NMS is characterized by fever, muscle rigidity, and neurologic changes after treatment with neuroleptic agents such as haloperidol. These symptoms may progress to rhabdomyolysis and acute renal failure. Many similar disease entities, especially those that display hyperpyrexia, resemble NMS. Thus, the diagnosis should rest on pertinent history as well as the recognition of these relevant clinical signs. Treatment should be directed toward averting the systemic complications of drug-induced rhabdomyolysis and renal failure. Discontinuation of the neuroleptic medication is imperative. Aggressive iv hydration, systemic and urine alkalinization, and therapy for life-threatening electrolyte abnormalities are all appropriate additional therapeutic goals. The use of dantrolene or bromocriptine may hasten recovery from NMS. Although mortality from NMS alone is unusual, NMS with concomitant renal failure carries a worse prognosis. The treatments outlined here may avert progressive renal failure and reduce mortality in patients with NMS-induced rhabdomyolysis and renal failure.
The Surgical Checklist
Authors: William Berry, Alex Haynes, Janaka Lagoo
Journal: JAMA Surgery (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Synthesis and characterization of anti-bacterial and anti-fungal citrate-based mussel-inspired bioadhesives
Authors: Jinshan Guo, Wei Wang, Jianqing Hu, Denghui Xie, Ethan Gerhard, Merisa Nisic, Dingying Shan, Guoying Qian, Siyang Zheng, Jian Yang
Journal: Biomaterials (2016)
Consistent detection of TLS/FUS-ERG chimeric transcripts in acute myeloid leukemia with t(16 ; 21) (p11 ; q22) and identification of a novel transcript
Authors: Xiao-Tang Kong, Kohmei Ida, Hitoshi Ichikawa, Kimiko Shimizu, Misao Ohki, Nobuo Maseki, Yasuhiko Kaneko, Masahiro Sako, Yukio Kobayashi, Arinobu Tojou, Ikuo Miura, Harumi Kakuda, Tetsunori Funabiki, Keizo Horibe, Hiroyuki Hamaguchi, Yuichi Akiyama, Fumio Bessho, Masayoshi Yanagisawa, Yasuhide Hayashi
Journal: Blood (1997)
Spontaneous Fibrosarcoma in a Thymus-Transplanted Nude Mouse: Brief Communication 2
Authors: E. A. Machado, S. V. Lair, R. S. Gregory
Journal: JNCI Journal of the National Cancer Institute (1977)

Journal Article Spontaneous Fibrosarcoma in a Thymus-Transplanted Nude Mouse: Brief Communication Get access E. A. Machado, E. A. Machado Search for other works by this author on: Oxford Academic PubMed Google Scholar S. V. Lair, S. V. Lair Search for other works by this author on: Oxford Academic PubMed Google Scholar R. S. Gregory R. S. Gregory Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 58, Issue 6, June 1977, Pages 1863–1865, https://doi.org/10.1093/jnci/58.6.1863 Published: 01 June 1977 Article history Received: 28 October 1976 Accepted: 04 January 1977 Published: 01 June 1977
Oxaliplatin, irinotecan, and 5-fluorouracil/leucovorin in advanced gastric adenocarcinoma: A phase II trial
Authors: P. Comella, V. Lorusso, L. Maiorino, R. Casaretti, M. Cannone, B. Massidda, A. Farris, S. Leo, M. Roselli, C. Sandomenico, S. Mancarella
Journal: Journal of Clinical Oncology (2008)

4542 Background: 5-fluorouracil (5FU)/leucovorin (LV) still remains the mainstay for the management of patients (pts) with metastatic gastric carcinoma, but long term results are still unsatisfactory. Oxaliplatin (OXA) and irinotecan (IRI) have shown interesting activity in combination with 5FU and LV in these pts. A triplet regimen incorporating all these active agents could be more effective than each doublets. Methods: Pts with locally advanced, unresectable or metastatic gastric or gastro-esophageal junction (GEJ) adenocarcinoma were eligible for this phase II study. Treatment consisted of OXA 85 mg/sqm (2-h i.v. infusion), and IRI 150 mg/sqm (30–90 min i.v. infusion) on day 1; 6S-LV 250 mg/sqm (2-h i.v. infusion) and 5FU 750 mg/sqm i.v. bolus on day 2. Cycles were repeated every 2 weeks for a maximum of 12 cycles. The Simon’s two-stage design required more than 16 responses among the first 46 pts to enroll 19 more pts. The final sample size of 65 pts has an 80% power to demonstrate a 45% response rate (RR) with a 5% alpha error. Results: From July 2005 to February 2007, 46 pts (males, 33; females, 13) were enrolled by 11 SICOG centers. Thirty-three pts had a gastric, and 13 pts a GEJ adenocarcinoma. Median age was 61 (range, 40–81) yrs. Twenty-one pts were in ECOG PS 0, 24 pts in PS 1, and 1 pt in PS 2. Disease was locally advanced in 2 pts, and metastatic in 44 pts. 6 pts had 1 site, 40 pts ≥ 2 sites of disease. Prior radical surgery had been performed in 18 pts, and 7 of them had also received adjuvant 5FU-based therapy. A total of 331 triplet cycles were administered, with a median of 8 (range, 4–12) cycles/pt. Most common WHO G ≥3 toxicity by pts were: neutropenia (39%), vomiting (24%), diarrhea (9%), and febrile neutropenia (7%). Two CRs and 15 PRs were registered, for an overall response rate of 37%; 20 pts achieved a SD. Since the activity required in the first stage has been achieved, a total of 65 pts have been acrrued. Conclusion: This preliminary analysis demonstrated the tolerability and promising activity of the triplet regimen in advanced/metastatic gastric or GEJ adenocarcinoma. Updated activity on the final sample size, as well as pts follow-up will be presented at the meeting. No significant financial relationships to disclose.
Evolution of androgen-regulated mRNA expression in mouse kidney.
Authors: J Tseng-Crank, C Schonfeld, F G Berger
Journal: Molecular Biology and Evolution (1988)

To gain information on the evolution of mammalian gene expression patterns, we studied the androgen-inducible expression of three kidney mRNAs in several mouse species (genus Mus). The RP2, ornithine decarboxylase, and beta-glucuronidase mRNAs have each evolved independently, in that the pattern of variation among species is unique for each. This suggests a role for gene-specific, cis-acting genetic elements. Relationships between the regulatory phenotypes and the species phylogeny suggest that the variations in hormone-inducible mRNA expression were generated by a series of independent mutations that occurred in specific lineages, resulting in modifications of the progenitor phenotype. Alternatively, the variations may have preexisted within the progenitor population as polymorphisms that were fixed during establishment of individual lineages. Thus, significant alterations in the androgen-regulated mRNA phenotype have occurred either prior to or during speciation within the Mus genus. These alterations are presumed to be in regulatory sequences that control the expression of the corresponding genes and their response to testosterone; as such, they should be useful in further studying the genetic determinants of gene expression and its evolution.
Incidence of Tumor-Cell Contamination in Leukapheresis Products of Breast Cancer Patients Mobilized With Stem Cell Factor and Granulocyte Colony-Stimulating Factor (G-CSF) or With G-CSF Alone
Authors: Wilbur A. Franklin, John Glaspy, Sean M. Pflaumer, Roy B. Jones, Lisa Hami, Charles Martinez, James R. Murphy, Elizabeth J. Shpall
Journal: Blood (1999)
Feasibility of treatment of resectable rectal cancer with neoadjuvant treatment with pemetrexed
Authors: G. Carlsson, H. Bjökqvist, G. Kurlberg, S. Torbjörn, M. Casillas, M. Holmqvist, C. Stoffregen, B. Gustavsson
Journal: Journal of Clinical Oncology (2009)

e15121 Background: Multimodality strategies of chemo- and radiotherapy (RT) in the neoadjuvant setting of resectable rectal cancer are a challenge to optimize surgery outcome. Pemetrexed (P) has shown efficacy in colorectal cancer. This phase II trial evaluated its feasibility as neo-adjuvant monotherapy for patients (pts) with resectable rectal cancer. Methods: Between June’ 06 and January’ 08, 37 pts with a histologically proven diagnosis of operable rectal adenocarcinoma were enrolled. P was dosed at 500 mg/m 2 every 3 weeks, during 3 cycles with standard co-medication (vitamin B 12 , folic acid, and dexamethasone) on an outpatient base. If RT was given, minimum interval between start of RT and last dose of P was 2 weeks, preferably 5 consecutive days of RT occurred from day 17 to day 21 in cycle 3 or after completion of cycle 3. The feasibility hypothesis was that at least 85% of pts would be able to receive the chemotherapy as planned. Secondary endpoints were evaluation of qualitative and quantitative toxicities including rate of postoperative complications, proportion of pts with sphincter saving surgery, proportion of pts with complete tumor resection rate and pathological response rate. Results: All patients were able to receive 3 cycles of chemotherapy. 33 patients (89.2%, CI: 74.6 to 97) completed their planned dosage in time. The reason for delay was inadequate vitamin supply for 1 pt and 3 pts due to other reasons. No dose reduction or study-drug related SAE was seen. The only grade 3 and 4 toxicities (neutropenia) occurred in 7 pts (18.9%). 28 pts received RT following chemotherapy. All pts underwent R0 resection. One pathological proven complete response was evaluated. 12 out of 13 planned pts had a rectum amputation. All others received sphincter saving surgery. Postoperative complications occurred in 54% of the pts. All events were considered related to study procedure (operation) and not to study drug. Conclusions: This explorative study suggests that the administration of 3 cycles of pemetrexed is feasible and well tolerated within a multimodality treatment strategy. [Table: see text]
Piperazinedione, total body irradiation, and autologous bone marrow transplantation in chronic myelogenous leukemia.
Authors: L Vellekoop, A R Zander, H M Kantarjian, S Jagannath, J P Hester, J Trujillo, K B McCredie, G Zagars, G Spitzer, K A Dicke
Journal: Journal of Clinical Oncology (1986)

Eleven patients with Philadelphia chromosome (Ph1)-positive chronic myelogenous leukemia (CML) in blast crisis (ten patients) or accelerated disease (one patient) were treated with piperazinedione (PIP) and fractionated total body irradiation (TBI) followed by autologous bone marrow transplantation (ABMT). Three patients were transplanted with marrow from which the Ph1 clone had been eradicated by prior intensive chemotherapy. All patients responded with disappearance of blasts in bone marrow and peripheral blood. Six patients achieved a second chronic phase lasting 3 to 14 months (median, 6 months). Two patients had incomplete recovery, and three patients failed to engraft and died from infection. Transplantation with Ph1-negative bone marrow did not improve response duration or survival. Recurrence of blast crisis and incomplete engraftment continue to be the two major problems in this patient group, and more active regimens need to be investigated.
Gene methylation and cytogenetic abnormalities in patients (pts) with higher-risk myelodysplastic syndromes.
Authors: G. J. Mufti, J. G. Herman, S. Gore, J. F. Seymour, V. Santini, A. M. Hagemeijer, B. Skikne, K. J. MacBeth, L. M. Lucy, C. L. Beach
Journal: Journal of Clinical Oncology (2010)

6606 Background: Inactivation of tumor-suppressor genes by DNA hypermethylation of CpG islands in gene promoter regions occurs frequently in MDS. We explored the relationship between methylation in gene promoter regions of 3 genes implicated in MDS and common cytogenetic abnormalities in pts in the AZA-001 trial, which showed a survival advantage in higher-risk MDS with AZA versus conventional care. Methods: Baseline bone marrow (BM) aspirates were evaluated for karyotype and DNA methylation of SOCS1, E-cadherin, and p15 genes in pts with higher-risk MDS (FAB RAEB, RAEB-T, or CMML and IPSS Int-2 or High). Four karyotypic categories were evaluated: normal, -5/5q-, -7/7q-, and trisomy 8 (+8). Methylation was determined using quantitative real-time methylation-specific PCR. Odds ratios (OR) for likelihood of methylation (any vs none) on each gene by karyotype were assessed, as were associations between baseline disease indices and methylation. Results: Methylation data were available for 112/153 pts with normal karyotypes, and 106/136 pts with -5/5q-, -7/7q-, and/or +8 abnormalities. Methylation was frequently present on all 3 genes. In pts with normal karyotypes, SOCS1 was most often not methylated (Table),but there was a strong association between SOCS1 methylation and -5/5q- (OR=3.44; p=0.0002). No other OR for methylation by karyotype was significant. Presence of methylation on the 3 genes was proportionately more frequent in pts with Good IPSS cytogenetic risk, pts with >10% to ≤20% BM blasts, and pts with abnormal cytogenetics. Conclusions: This is the first analysis to examine relationships between gene methylation and specific cytogenetic abnormalities. SOCS1 methylation was more frequently observed in pts with -5/5q- than in pts with normal cytogenetics. Associations between methylation and karyotype may provide insight on responsiveness of karyotypic subgroups to hypomethylating therapy. Methylation by karyotype Gene Normal Abnormal -5/5q- -7/7q- +8 Presence of methylation, n (%) No Yes No Yes No Yes No Yes E-Cadherin 12 (11) 100 (89) 11 (19) 47 (81) 6 (14) 36 (86) 5 (14) 32 (86) SOCS1 66 (59) 46 (41) 14 (24) 44 (76) 14 (33) 28 (67) 16 (43) 21 (57) p15 20 (19) 87 (81) 12 (21) 46 (79) 6 (15) 35 (85) 5 (14) 31 (86) Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Celgene Celgene, OncoMethylome Sciences Celgene Celgene Celgene, OncoMethylome Sciences Celgene
Partial breast irradiation or whole breast radiotherapy for early breast cancer: A meta-analysis of randomized controlled trials
Authors: A. Valachis, D. Mauri, N. P. Polyzos, D. Mavroudis, V. Georgoulias, G. Casazza
Journal: Journal of Clinical Oncology (2009)

CRA532 The full, final text of this abstract will be available in Part II of the 2009 ASCO Annual Meeting Proceedings, distributed onsite at the Meeting on May 30, 2009, and as a supplement to the June 20, 2009, issue of the Journal of Clinical Oncology. No significant financial relationships to disclose.
Multiparametric Magnetic Resonance Imaging (MRI) and MRI–Transrectal Ultrasound Fusion Biopsy for Index Tumor Detection: Correlation with Radical Prostatectomy Specimen
Authors: Jan P. Radtke, Constantin Schwab, Maya B. Wolf, Martin T. Freitag, Celine D. Alt, Claudia Kesch, Ionel V. Popeneciu, Clemens Huettenbrink, Claudia Gasch, Tilman Klein, David Bonekamp, Stefan Duensing, Wilfried Roth, Svenja Schueler, Christian Stock, Heinz-Peter Schlemmer, Matthias Roethke, Markus Hohenfellner, Boris A. Hadaschik
Journal: European Urology (2016)